Kura Oncology, Inc. (KURA) Stock Research
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Latest price: 10.805 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| FORD KATHLEEN | sell | 2026-09-29 | 39436.87 |
| FORD KATHLEEN | sell | 2026-09-28 | 72494.35 |
| Powl Brian T. | sell | 2026-09-28 | 84497.6 |
| Leoni Mollie | sell | 2026-09-29 | 309566.78 |
| Powl Brian T. | sell | 2026-09-29 | 165852.44 |
| Bair Teresa Brophy | sell | 2026-09-28 | 88618.21 |
| Powl Brian T. | sell | 2026-09-28 | 94685.65 |
| DOYLE THOMAS JAMES | sell | 2026-09-28 | 48360.6 |
| Leoni Mollie | sell | 2026-09-28 | 130670.39 |
| Burrows Francis | sell | 2026-09-24 | 224514.4 |